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Pseudomonas aeruginosa is an opportunistic pathogen of hosts with impaired 
immune function or concurrent disease, most notably patients with Cystic 
Fibrosis and those who have been severely burned. It has an extensive array of 
virulence factors (VFs) which enable it to colonise and penetrate host tissue.  It 
is responsible for a high percentage of nosocomial infections and is becoming 
increasingly antibiotic resistant, so there is an immediate need for novel 
treatments of severe P. aeruginosa infections.  Following severe traumatic 
injury to the skin, the dermis and epidermis may be destroyed, leaving the 
fascia and endothelium of the vasculature as the final structural barriers 
protecting the circulation and preventing bacteraemia.  Little has been reported 
on the mechanisms used by P. aeruginosa to penetrate the fascia and enter the 
circulation, because conventional animal models of dermal injury do not allow 
for quantitative study of bacterial pathogenesis and host responses.  To 
address this, a novel transdermal chamber was designed, manufactured and 
implanted into mice allowing for repeated sampling and quantitative analysis of 
bacterial replication, VFs, and host responses. Despite the bacterial load in the 
chamber exudate being similar to normal control mice, mice immunosuppressed 
using cyclophosphamide (CP) had significantly higher levels of Exotoxin A 
(ETA), P. aeruginosa elastase (PAE) and Phospholipase C (PLC), and 
developed fatal bacteraemia when compared to immunocompetent mice.     
 
It was hypothesised that raised levels of ETA and PAE contributed to the 
pathogenesis of P. aeruginosa in CP treated mice by increasing the 
permeability of the fascia and endothelium allowing bacteria to enter the 
circulation.  To test this, purified ETA and PAE were added to the chambers of 
immunocompetent mice, followed by fluorescently labelled dextran to assess 
efflux measured as a change in dextran concentration in the chamber exudate 
over time.  ETA caused sustained local depletion of leukocytes and fibroblasts, 
reduction in exudate volume and weight loss, but did not change the dextran 
concentration in the chamber exudate compared to control mice.  PAE was pro-
inflammatory, increased exudate volume, damaged fascial tissue, induced local 
haemorrhage, and resulted in a decrease in dextran concentration in the 




resulted in increased weight loss, haemoglobinaemia and increased 
accumulation of dextran in the local draining lymph nodes.  
 
Preliminary trials using ovine anti-sera to P. aeruginosa antigens in infected 
chambers of CP-treated mice increased their survival. Collectively, these results 
show that the increased concentration of VFs, not bacterial load, facilitated 
bacterial translocation across the fascia and endothelium, and uncovers the 
underlying significance of the superficial fascia as a defensive barrier against 
infectious agents.  Furthermore, this study suggests that neutrophils are crucial 
to reducing VF concentration, and that topically applied heterologous anti-P. 
aeruginosa antibodies may be useful in preventing fatal bacteraemia in severe 
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